Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Global TAR DNA-Binding Protein 43 (TDP-43) Pipeline Report 2016 - Review of 5 Companies/Institutions & 7 Molecules - Research and Markets

Research and Markets
Posted on: 31 Aug 16

Research and Markets has announced the addition of the "TAR DNA-Binding Protein 43 (TDP-43) - Pipeline Review, H1 2016" report to their offering.

TAR DNA-Binding Protein 43 (TDP-43) pipeline target constitutes close to 7 molecules, out of which approximately 7 molecules are developed by companies. The report "TAR DNA-Binding Protein 43 - Pipeline Review, H1 2016" outlays comprehensive information on the TAR DNA-Binding Protein 43 (TDP-43) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

TAR DNA-Binding Protein 43 (TDP-43) TAR DNA-binding protein 43 or TDP-43 is a protein encoded by the TARDBP gene. It is involved in the regulation of CFTR splicing, microRNA biogenesis, apoptosis and cell division. It represses HIV-1 transcription by binding to the HIV-1 long terminal repeat. It stabilizes the low molecular weight neurofilament mRNA through a direct interaction with the 3' UTR. The molecules developed by Companies in Phase III, Preclinical and Discovery stages are 1, 3 and 3 respectively.

Furthermore, this report also reviews key players involved in TAR DNA-Binding Protein 43 (TDP-43) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

Key Topics Covered:

  1. Introduction
  2. TAR DNA-Binding Protein 43 Overview
  3. Therapeutics Development
  4. Pipeline Products for TAR DNA-Binding Protein 43 - Overview
  5. Pipeline Products for TAR DNA-Binding Protein 43 - Comparative Analysis
  6. TAR DNA-Binding Protein 43 - Therapeutics under Development by Companies
  7. TAR DNA-Binding Protein 43 - Therapeutics under Investigation by Universities/Institutes
  8. TAR DNA-Binding Protein 43 Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. TAR DNA-Binding Protein 43 - Products under Development by Companies
  13. TAR DNA-Binding Protein 43 - Products under Investigation by Universities/Institutes
  14. TAR DNA-Binding Protein 43 - Companies Involved in Therapeutics Development
  • Biogen, Inc.
  • ImStar Therapeutics Inc.
  • Primary Peptides, Inc.
  • SK Biopharmaceuticals Co., Ltd.
  • TauRx Therapeutics Ltd.

For more information about this report visit http://www.researchandmarkets.com/research/ldvbhm/tar_dnabinding

Related Topics: Central Nervous System Drugs

View source version on businesswire.com: http://www.businesswire.com/news/home/20160831005766/en/

Business Wire
www.businesswire.com

Last updated on: 31/08/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.